Medicine Supply Notification: Lisdexamfetamine (Elvanse®) capsules

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Lisdexamfetamine (Elvanse®) capsules

MSN/2024/051

Tier 3 high impact

Date of issue: 8th May 2024

  • All strengths of Elvanse® capsules are now available and an improved level of supply will continue across the majority of Elvanse® and Elvanse Adult® presentations.
  • There will however be intermittent supply issues with Elvanse® 40mg, Elvanse® Adult 40mg and Elvanse® 60mg capsules until August 2024.
  • Elvanse® 20mg capsules remain available, but, cannot support an increase in demand during shortages of Elvanse® 40mg, Elvanse® Adult 40mg and Elvanse® 60mg capsules
  • Elvanse® 30mg capsules remain available and can support an increase in demand during the shortage of Elvanse 60mg capsules.
  • All ADHD service providers can recommence initiating new and deferred patients on Elvanse® and Elvanse® Adult capsules and should consider utilising the 30mg, 50mg & 70mg titration schedule, where possible.
  • Unlicensed supplies of lisdexamfetamine capsules can be sourced, lead times vary.
  • Generic dexamfetamine 5mg tablets and Amfexa (dexamfetamine) 5mg, 10mg, and 20mg tablets remain available but are unable meet large increases in demand.
  • This guidance supersedes MSN/2024/019 issued in February 2024.

Unlicensed products

The following specialist importers have confirmed they can source unlicensed Elvanse® capsules (please note there may be other companies that can also source supplies):

The following Specials manufacturers have confirmed they can supply unlicensed lisdexamfetamine capsules (please note there may be other companies that can also source supplies):

If there is currently no listing on dm+d for the imported product for prescribers to select using their prescribing systems an EPS prescription for the unlicensed product cannot be issued. Where a prescriber wishes to prescribe a specially manufactured or imported product, an FP10 paper prescription should be issued as ‘ Vyvanse or Elvanse (Special Order)’ and endorsed by the pharmacy as a non-Part VIIIB special with the following information:

  • Amount dispensed over pack size used;
  • Invoice price per pack size from which the order was supplied less any discount or rebate;
  • Manufacturers’/importers’ MHRA licence number;
  • Batch number of the product supplied;
  • SP

A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses.

DHSC and NHSE/I have now launched an online Medicines Supply Tool, which provides up to date information about medicine supply issues. The contents of these MSNs can now be viewed on the Tool.

The Tool also details any changes to resupply dates and updates to the entries.

To access the Tool you will need  an NHS email address. Once set up and logged in, you will be able to access it online.

New shortages not listed on the SPS website, can be reported using our shortage reporting tool.

Capture healthcare advisory work not being covered by Pharmacy First to inform our negotiations with Government and NHS.

Click Here